In­ves­ti­ga­tors sound a safe­ty alarm af­ter 2 pa­tients die of heart con­di­tion fol­low­ing check­point com­bo

Check­point in­hibitors like Keytru­da and Op­di­vo quick­ly achieved leg­endary sta­tus as break­through can­cer ther­a­pies with broad, block­buster roles to play on the mar­ket. But in a new study pub­lished in the New Eng­land Jour­nal of Med­i­cine, in­ves­ti­ga­tors have spot­light­ed rare cas­es in which check­point pa­tients have died or been af­flict­ed by heart trou­ble. And there’s ev­i­dence that a T-cell dri­ven re­ac­tion threat­ens a very small group of pa­tients tak­ing the drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.